长期促红细胞生成素治疗对血液透析尿毒症患者血浆钙磷相关激素水平的影响。
Influence of long-term erythropoietin treatment on plasma levels of calcium-phosphate related hormones in haemodialyzed uraemic patients.
作者信息
Kokot F, Wiecek A, Marcinkowski W, Schmidt-Gayk H, Rudka R, Trembecki J
机构信息
Department of Nephrology, Silesian University School of Medicine, Katowice, Poland.
出版信息
Ann Univ Mariae Curie Sklodowska Med. 1994;48 Suppl 3:9-16.
Exacerbation of secondary hyperparathyroidism (as manifested by calcium deposits and local inflammation in periarticular tissues) has been reported in haemodialyzed (HD) uraemic patients treated with recombinant human erythropoietin. However, short-term treatment with recombinant human erythropoietin (r-Hu EPO) did not influence significantly plasma levels of parathyroid hormone (PTH), calcitonin (CT) and 25-hydroxycholecalciferol (25-OHD3) in uraemic HD patients. The present study aimed to assess the effect of long-term r-Hu EPO therapy for 12 months on plasma PTH, CT, 25-OHD3 and 1,25-dihydroxycholecalciferol (1,25-(OH)2D3) in uraemic HD patients.
据报道，接受重组人促红细胞生成素治疗的血液透析（HD）尿毒症患者会出现继发性甲状旁腺功能亢进加重（表现为关节周围组织中的钙沉积和局部炎症）。然而，重组人促红细胞生成素（r-Hu EPO）短期治疗对尿毒症HD患者的甲状旁腺激素（PTH）、降钙素（CT）和25-羟胆钙化醇（25-OHD3）血浆水平无显著影响。本研究旨在评估尿毒症HD患者长期接受r-Hu EPO治疗12个月对血浆PTH、CT、25-OHD3和1,25-二羟胆钙化醇（1,25-(OH)2D3）的影响。
Zotero 插件